JP2025507923A5 - - Google Patents
Info
- Publication number
- JP2025507923A5 JP2025507923A5 JP2024552265A JP2024552265A JP2025507923A5 JP 2025507923 A5 JP2025507923 A5 JP 2025507923A5 JP 2024552265 A JP2024552265 A JP 2024552265A JP 2024552265 A JP2024552265 A JP 2024552265A JP 2025507923 A5 JP2025507923 A5 JP 2025507923A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pclx
- per day
- hours
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316153P | 2022-03-03 | 2022-03-03 | |
| US63/316,153 | 2022-03-03 | ||
| PCT/CA2023/050281 WO2023164776A1 (en) | 2022-03-03 | 2023-03-03 | Oral pclx-001 in the treatment of human cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507923A JP2025507923A (ja) | 2025-03-21 |
| JP2025507923A5 true JP2025507923A5 (https=) | 2026-03-12 |
Family
ID=87882761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552265A Pending JP2025507923A (ja) | 2022-03-03 | 2023-03-03 | ヒトがんの処置における経口ｐｃｌｘ－００１ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250161299A1 (https=) |
| EP (1) | EP4486344A4 (https=) |
| JP (1) | JP2025507923A (https=) |
| KR (1) | KR20240155234A (https=) |
| CN (1) | CN118829428A (https=) |
| AU (1) | AU2023228703A1 (https=) |
| CA (1) | CA3244234A1 (https=) |
| IL (1) | IL314984A (https=) |
| MX (1) | MX2024010584A (https=) |
| WO (1) | WO2023164776A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025050208A1 (en) * | 2023-09-05 | 2025-03-13 | Pacylex Pharmaceuticals Inc. | Oral pclx-001 in the treatment of human cancer |
| CN120361006A (zh) * | 2025-05-19 | 2025-07-25 | 上海交通大学医学院附属第九人民医院 | Nmt1抑制剂及其在制备实体瘤治疗药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974967B (zh) * | 2012-10-30 | 2023-11-07 | 厄尔莱克斯制药公司 | 合成致死与癌症的治疗 |
| JP7539760B2 (ja) * | 2015-07-17 | 2024-08-26 | パシレックス・ファーマシューティカルズ・インコーポレイテッド | Ｎｍｔ２の後成的なサイレンシング |
| GB201820660D0 (en) * | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
| MX2023004341A (es) * | 2020-10-20 | 2023-05-24 | Pacylex Pharmaceuticals Inc | Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios. |
-
2023
- 2023-03-03 KR KR1020247029643A patent/KR20240155234A/ko active Pending
- 2023-03-03 CA CA3244234A patent/CA3244234A1/en active Pending
- 2023-03-03 AU AU2023228703A patent/AU2023228703A1/en active Pending
- 2023-03-03 CN CN202380025222.6A patent/CN118829428A/zh active Pending
- 2023-03-03 US US18/841,472 patent/US20250161299A1/en active Pending
- 2023-03-03 EP EP23762647.8A patent/EP4486344A4/en active Pending
- 2023-03-03 WO PCT/CA2023/050281 patent/WO2023164776A1/en not_active Ceased
- 2023-03-03 MX MX2024010584A patent/MX2024010584A/es unknown
- 2023-03-03 IL IL314984A patent/IL314984A/en unknown
- 2023-03-03 JP JP2024552265A patent/JP2025507923A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025507923A5 (https=) | ||
| JPWO2023190748A5 (https=) | ||
| NZ590431A (en) | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor | |
| JP2023515235A5 (https=) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2016528162A5 (https=) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| JP2022533578A5 (https=) | ||
| RU2013134359A (ru) | Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований | |
| JP2021513536A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2024506612A5 (https=) | ||
| WO2005084712A3 (en) | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment | |
| JP2016522202A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| JP2023542093A5 (https=) | ||
| CN104582708A (zh) | 用于治疗小细胞肺癌的苯并二氮*类 | |
| CN111936143A (zh) | 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 | |
| GEAP202416383A (en) | Use of medicament in treatment of tumor disease | |
| Campana et al. | The value of electrochemotherapy in the treatment of peristomal tumors | |
| NZ598652A (en) | Cancer cell apoptosis | |
| JP2014005265A5 (https=) | ||
| JP2023515687A5 (https=) | ||
| NO20084635L (no) | Fosfor inneholdende forbindelser inkludert trifenylmetylfosfonat estere for behandlingen av melanoma og andre kreftformer | |
| JP2020520385A5 (https=) |